Evidence map›Paper›PMID 33066658›Full record

ArticleNanomaterials (Basel, Switzerland)2020

Paper-Based In-Situ Gold Nanoparticle Synthesis for Colorimetric, Non-Enzymatic Glucose Level Determination.

Tomás Pinheiro, João Ferrão, Ana C Marques, Maria J Oliveira, Nitin M Batra, Pedro M F J Costa, M Paula Macedo, Hugo Águas, Rodrigo Martins, Elvira Fortunato

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Tomás PinheiroCENIMAT/i3N, Materials Science Department, Faculdade de Ciência e Tecnologia-Universidade Nova de Lisboa, Lisbon 2829-516, Portugal.
João FerrãoCENIMAT/i3N, Materials Science Department, Faculdade de Ciência e Tecnologia-Universidade Nova de Lisboa, Lisbon 2829-516, Portugal.
Ana C MarquesCENIMAT/i3N, Materials Science Department, Faculdade de Ciência e Tecnologia-Universidade Nova de Lisboa, Lisbon 2829-516, Portugal.
Maria J OliveiraCENIMAT/i3N, Materials Science Department, Faculdade de Ciência e Tecnologia-Universidade Nova de Lisboa, Lisbon 2829-516, Portugal.
Nitin M BatraPhysical Science and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.
Pedro M F J CostaPhysical Science and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.
M Paula MacedoCEDOC, Chronic Disease Research Centre, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo Mártires da Pátria, Lisbon 1150-190, Portugal.
Hugo ÁguasCENIMAT/i3N, Materials Science Department, Faculdade de Ciência e Tecnologia-Universidade Nova de Lisboa, Lisbon 2829-516, Portugal.
Rodrigo MartinsCENIMAT/i3N, Materials Science Department, Faculdade de Ciência e Tecnologia-Universidade Nova de Lisboa, Lisbon 2829-516, Portugal.
Elvira FortunatoCENIMAT/i3N, Materials Science Department, Faculdade de Ciência e Tecnologia-Universidade Nova de Lisboa, Lisbon 2829-516, Portugal.
Universidade Nova de Lisboa · PTKing Abdullah University of Science and Technology · SAAssociacao Protectora dos Diabeticos de Portugal · PT

Funding

European Research Council DIGISMART ref. 787410FCT-MCTES SFRH/BD/115173/2016FCT-MCTES SFRH/BD/132057/2017FCT-MCTES UID/CTM/50025/2013FEDER iNOVA4Health - UID/Multi/04462/2013
6 · The paper itself

Abstract

Due to its properties, paper represents an alternative to perform point-of-care tests for colorimetric determination of glucose levels, providing simple, rapid, and inexpensive means of diagnosis. In this work, we report the development of a novel, rapid, disposable, inexpensive, enzyme-free, and colorimetric paper-based assay for glucose level determination. This sensing strategy is based on the synthesis of gold nanoparticles (AuNPs) by reduction of a gold salt precursor, in which glucose acts simultaneously as reducing and capping agent. This leads to a direct measurement of glucose without any enzymes or depending on the detection of intermediate products as in conventional enzymatic colorimetric methods. Firstly, we modelled the synthesis reaction of AuNPs to determine the optical, morphological, and kinetic properties and their manipulation for glucose sensing, by determining the influence of each of the reaction precursors towards the produced AuNPs, providing a guide for the manipulation of nucleation and growth. The adaptation of this synthesis into the developed paper platform was tested and calibrated using different standard solutions with physiological concentrations of glucose. The response of the colorimetric signals obtained with this paper-based platform showed a linear behavior until 20 mM, required for glycemic control in diabetes, using the Red × Value/Grey feature combination as a calibration metric, to describe the variations in color intensity and hue in the spot test zone. The colorimetric sensor revealed a detection limit of 0.65 mM, depending on calibration metric and sensitivity of 0.013 AU/mM for a linear sensitivity range from 1.25 to 20 mM, with high specificity for the determination of glucose in complex standards with other common reducing interferents and human serum.

Indexed as

colorimetricdiabetesenzyme-freeglucosegold nanoparticlesin-situ synthesispaper-based platform

Identifiers

PMID33066658
PMCPMC7602483
OpenAlexW3093254192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.